Evidence review

ARA-290 vs Gabapentin: Nerve Repair vs Symptom Masking

#peptide#topic
bundle · json · system map · manifest

Every copy includes §SELF — what this is, proof chain, and links to every other feature. No context required.

§SELF — this page explains the system
## §SELF — miscsubjects (paste without context)

**Principle:** Self-explaining payload — no external context required. This _self block describes what you are reading and where to look next.

**This widget:** `human_page` — **Human article page**
Rendered article with claims, sources, copy widgets, ask prompts.
- **article slug:** `ara-vs-gabapentin-comparison`
- **contains:** rendered article, copy widgets, claims, sources, ask prompts
- **how to use:** Use Copy for LLM or Copy system map — both paste without context.
- **read:** https://miscsubjects.com/a/ara-vs-gabapentin-comparison

### Logical proof (verify each step)
1. Articles are voxel graphs of tiered claims, not prose blobs. → https://miscsubjects.com/api/articles/constitution
2. Claims link to hash-chained sources via source_ids. → https://miscsubjects.com/api/articles/ara-vs-gabapentin-comparison/sources
3. Ask reads topology; ingest/claim append to ledger. → https://miscsubjects.com/api/protocol
4. Models queue growth: populate → collaborate → repair → reflex. → https://miscsubjects.com/api/protocol/grow
5. Graph proves its own shape (reflex) and $/claim (yield). → https://miscsubjects.com/graph.html?layer=reflex
6. Full feature index + _explain on every API response. → https://miscsubjects.com/api/articles/system-map

### Related features (explains other parts of the system)
- **bundle** — Paste-ready package: body + claims + sources + voxels + provenance + manifest + constitution. · https://miscsubjects.com/api/articles/ara-vs-gabapentin-comparison/bundle?format=markdown
- **ask** — Answer only from topology; creates question_node with gaps and ingest_hint. · https://miscsubjects.com/api/articles/ara-vs-gabapentin-comparison/prompts
- **topology** — Claims, sources, anecdotes, user reports, related embeds, question graph slice — for ask/ROUTER. · https://miscsubjects.com/api/articles/ara-vs-gabapentin-comparison/topology

### Full index
- JSON: https://miscsubjects.com/api/articles/system-map
- Markdown: https://miscsubjects.com/api/articles/system-map?format=markdown

*Not medical advice. Tier-honest. Cite claim/source ids.*
What is known
  • Detailed review emphasizing Phase 2 data on nerve regeneration markers vs symptomatic masking by gabapentin; notes stalled development post-2020.
  • A review article highlights ARA-290 as a tissue-protective peptide for nerve pain.
  • ARA-290 treatment for 28 days initiated regrowth of small nerve fibers in the cornea in sarcoidosis patients.
What is not known
  • There is a lack of long-term studies on the safety and efficacy of ARA-290 in treating neuropathy.

Regeneration vs degeneration — where this fits

The body breaks tissue down and builds it back at the same time. When breakdown exceeds repair, small fiber nerves lose density and function. Gabapentin reduces pain signal transmission without changing nerve structure. ARA-290 is studied for activation of the innate repair receptor, which may shift the balance toward nerve regrowth and reduced inflammation.

What it is

ARA-290 is an 11-amino-acid peptide derived from erythropoietin that does not raise red blood cell count. Gabapentin is a prescription drug that binds the alpha-2-delta subunit of voltage-gated calcium channels.

How it works

ARA-290 binds the innate repair receptor formed by the EPO receptor and the beta-common receptor. Binding reduces NLRP3 inflammasome activity, lowers inflammatory cytokines, and supports small nerve fiber regrowth in some tissues. Gabapentin blocks presynaptic calcium influx, reduces glutamate release, and activates astrocytic glutamate uptake. These actions dampen pain signaling but do not restore nerve fibers.

Why it would work (logic chain)

If nerve loss drives neuropathic pain, restoring fiber density should reduce symptoms at the source. If inflammation maintains the degenerative state, lowering cytokine levels should slow further loss. If gabapentin only changes signal strength, pain returns when the drug leaves the system. If ARA-290 changes tissue structure, measured improvements in corneal nerve fiber density or skin biopsy should persist after the compound clears.

Why people take it

People take gabapentin to lower daily pain scores and improve sleep. People take ARA-290 in the hope of measurable nerve repair in addition to pain reduction. Some users report attempting to lower gabapentin dose after trying ARA-290.

How many people take it

No public registry tracks either compound for neuropathy. Gabapentin prescriptions number in the tens of millions annually in the United States. ARA-290 use outside trials is limited to unregulated sources; the developing company closed operations by 2026 and no active regulatory filing remains.

Evidence inventory

49 total sources catalogued: 25 studies or trial listings, 11 Reddit posts, 5 X posts, 5 other anecdotal sources. Human trial data: 1 Phase 2 study with corneal confocal microscopy. Preclinical data: 12 sources. Anecdotal reports: 23 sources. One source directly compares the two compounds on mechanism.

What scientists say

A 2015 Phase 2 trial in type 2 diabetes patients showed mean corneal nerve fiber density increased in the ARA-290 group while the placebo group showed no change (source s1). A 2012 pilot RCT in sarcoidosis patients found ARA-290 reduced neuropathic pain scores with no hematologic changes (source s37). A 2014 review of Phase 2 data reported consistent symptom improvement in sarcoidosis small fiber neuropathy (source s7). Reviews note that gabapentin reduces pain via presynaptic inhibition without evidence of structural nerve repair (source s2). A 2025 preclinical study in rats showed ARA-290 reduced NLRP3 activation and improved functional recovery after sciatic nerve crush (source s19). Development of ARA-290 has stalled; the sponsor closed with no active IND or NDA (source s24).

What people say on Reddit

One user reduced gabapentin from 2400 mg/day to 800-1600 mg/day after a 28-day ARA-290 course and reported symptom improvement in idiopathic small fiber neuropathy (source s6). Another user stated ARA-290 worked better than prior IVIG and produced relief within two hours, though ongoing use was required (source s12). A third user reported walking 14,000 steps pain-free after combining ARA-290 with a nerve stimulator and attributed the change to accelerated nerve repair (source s13). One user found initial ARA-290 benefit that faded and switched back to gabapentin for better symptom control (source s16). A user with disc herniation nerve pain reported no benefit or side effects after a short ARA-290 trial and noted allergy to gabapentin and pregabalin (source s15). Multiple users described partial return of foot sensation after one month of use (sources s30, s32).

What people say on X

One post states gabapentin masks the signal while ARA-290 targets the innate repair receptor to regrow fibers (source s33). Another post notes small nerves innervate organs beyond skin and lists ARA-290 among compounds that may regrow or repair nerves unlike gabapentin (source s34). A 2026 post references the 2018 Diabetes Care study showing restored small fiber density in diabetic neuropathy (source s44). One user expressed hope that ARA-290 would be life-changing for their neuropathy (source s29).

What we do not know

No large Phase 3 trial has confirmed sustained nerve fiber regeneration or long-term symptom relief. No head-to-head randomized trial exists between ARA-290 and gabapentin. Corneal nerve fiber density improvement has been measured, but correlation with skin biopsy or functional outcomes in other nerves remains limited. Duration of any repair effect after stopping ARA-290 is unknown. Real-world prevalence of use outside trials is not quantified.

Safety and limits

ARA-290 showed no change in hemoglobin or hematocrit in the published trials. Common gabapentin side effects include dizziness, sedation, and peripheral edema. Both compounds lack long-term safety data in large populations for neuropathy repair. ARA-290 is not available through regulated channels following sponsor closure.

Gabapentin · drug map

Evidence map

Hover a node — its path lights up. Click to open the article.

Full map →
JumpARA-290: Nerve Repair Peptide · 13 humanARA-290 vs Gabapentin and Lyrica: Human Trial Data on Nerve Repair Ver… · 13 humanARA-290 for Post-Surgical Nerve Damage: Evidence Review · 9 humanARA-290 for Carpal Tunnel: Human Trial Data on Nerve Symptoms and Fibe… · 8 human
Evidence · 63 sources · swipe →chain befeb25d9282 · verify chain · provenance
1 / 63

Key evidence

66 claims · tier-ranked · API
mechanistic
Hash-chained sources verify integrity, not clinical truth. Evidence mix is predominantly preclinical and anecdotal; human data are sparse. No dosing, protocol, or treatment recommendations — catalogue only.
human
Detailed review emphasizing Phase 2 data on nerve regeneration markers vs symptomatic masking by gabapentin; notes stalled development post-2020.
sources: s4
human
Review comparing ARA290's repair mechanism to standard symptom-masking treatments like gabapentin in neuropathy models and trials.
sources: s17
human
Not medical advice. Tier-honest research catalogue only — consult qualified healthcare professionals for personal health decisions.
human
A review article highlights ARA-290 as a tissue-protective peptide for nerve pain.
sources: s4
preclinical
2024 study demonstrating ARA290's neuroprotective and anti-inflammatory effects supporting nerve repair.
sources: s9
system
ARA-290 vs Gabapentin: Nerve Repair vs Symptom Masking is catalogued in this miscsubjects ledger as a tier-honest evidence graph (claims + hash-chained sources). This page summarizes what is claimed in the literature and online about the topic — not clinical recommendations.
anecdotal
Recent X anecdote expressing optimism about ARA-290 for personal neuropathy case.
sources: s29
anecdotal
User opinion: ARA-290 (with others) can regrow/repair nerves unlike Gabapentin which only masks symptoms.
sources: s34
anecdotal
June 2026 X post discusses ARA-290 restoring small fiber density in diabetic neuropathy, highlighting repair vs masking.
sources: s44
45 more ranked claims
anecdotal0.30
Recent X post discussing availability of ARA-290.
grok/grok-4.3
Materialized from orphan source s48 by ledger repair
sources: s48
anecdotal0.30
Anecdotal reports suggest ARA-290 may have varying effects among individuals, but specific details on these individual experiences are not provided.
kimi-collaborator
This claim identifies that while there are anecdotal reports about ARA-290, the specifics of who claims what are not detailed, which is a gap in the anecdotal evidence presented.
sources: s29, s34, s44, s48
anecdotal0.30
X post anecdote: ARA-290 amazing for nerve pain (good outcome). No dosing details. (anecdotal, not advice)
grok-4.3
Materialized from orphan source s55 by ledger repair
sources: s55
anecdotal0.30
X post recommending ARA-290 for radicular/nerve pain while tapering gabapentin; personal experience (anecdotal, not advice).
grok-4.3
Materialized from orphan source s60 by ledger repair
sources: s60
anecdotal0.30
Post suggesting ARA-290 as option to reduce reliance on gabapentin for nerve pain (anecdotal suggestion only).
grok-4.3
Materialized from orphan source s62 by ledger repair
sources: s62
human0.22downweightedlow confidence
ARA-290 treatment for 28 days initiated regrowth of small nerve fibers in the cornea in sarcoidosis patients.
grok/4.3-populate
Supports nerve repair framing with objective measure.
sources: s1
human0.22low confidence
Gabapentin inhibits release of excitatory neurotransmitters by binding calcium channels but does not heal damaged nerves.
grok/4.3-populate
Distinguishes symptom masking from repair.
sources: s2
human0.22low confidence
ARA-290 improved neuropathic symptoms in human trials for small fiber neuropathy associated with sarcoidosis or type 2 diabetes.
grok/4.3-populate
Provides human clinical trial data tier.
sources: s1
human0.22low confidence
2014 review of Phase II trials showing ARA290 improves neuropathic symptoms via tissue protection and repair mechanisms.
grok/grok-4.3
Materialized from orphan source s7 by ledger repair
sources: s7
human0.22
2024 Phase II trial exploring ARA290 (4mg SC) for diabetic complications, extending evidence base.
grok/grok-4.3
Materialized from orphan source s8 by ledger repair
sources: s8
human0.22
Ongoing or listed trial on ARA 290 for sarcoidosis neuropathy symptoms and nerve fiber density, distinct from listed NCT06626971.
grok/grok-4.3
Materialized from orphan source s35 by ledger repair
sources: s35
human0.22
Compares conventional symptom-masking like gabapentin (NNT 5.9) to ARA-290's nerve regeneration evidence in context of multi-domain leg pain treatment.
grok/grok-4.3
Materialized from orphan source s36 by ledger repair
sources: s36
human0.22
2012 pilot RCT showing ARA 290 reduces SFN symptoms safely in sarcoidosis patients via IRR activation for repair/anti-inflammation.
grok/grok-4.3
Materialized from orphan source s37 by ledger repair
sources: s37
human0.22
Phase I study on ARA290 (Cibinetide) effects on cognitive and neural processing of emotions in healthy volunteers; explores non-hematopoietic EPO analog for neural impacts relevant to neuropathy repair.
grok/grok-4.3
Materialized from orphan source s39 by ledger repair
sources: s39
human0.22
Phase II trial examining ARA290 effects on metabolic control and neuropathic symptoms in T2D patients, supporting nerve repair potential over symptom masking.
grok/grok-4.3
Materialized from orphan source s40 by ledger repair
sources: s40
human0.22low confidence
Expert review on ARA290 as promising option for neuropathic pain in sarcoidosis via tissue repair pathways, not mere masking.
grok/grok-4.3
Materialized from orphan source s43 by ledger repair
sources: s43
human0.22low confidence
2020 Phase 2 trial on cibinetide (ARA-290) for diabetic macular edema, related to its neuroprotective properties.
grok/grok-4.3
Materialized from orphan source s46 by ledger repair
sources: s46
human0.22low confidence
There is a lack of long-term studies on the safety and efficacy of ARA-290 in treating neuropathy.
kimi-collaborator
This claim addresses a gap in the evidence regarding the long-term effects of ARA-290, which is not covered by the existing preclinical and anecdotal sources.
sources: s1
anecdotal0.22low confidence
Multiple user anecdotes on ARA-290 use for neuropathy repair, with some combining or reducing gabapentin doses; reports of nerve flares or benefits.
grok/grok-4.3
Materialized from orphan source s5 by ledger repair
sources: s5
anecdotal0.22low confidence
Detailed self-report of ARA-290 protocol (4mg/day x28 days) leading to symptom improvement and ability to lower gabapentin in idiopathic SFN.
grok/grok-4.3
Materialized from orphan source s6 by ledger repair
sources: s6
anecdotal0.22low confidence
User anecdotes on ARA-290 providing rapid pain relief and possible nerve benefits, with ongoing use needed.
grok/grok-4.3
Materialized from orphan source s12 by ledger repair
sources: s12
anecdotal0.22low confidence
Recent anecdotal report of significant symptom improvement and implied repair from ARA-290 use.
grok/grok-4.3
Materialized from orphan source s13 by ledger repair
sources: s13
anecdotal0.22low confidence
User with nerve pain from herniated disc tried multiple meds including gabapentin (allergic), now self-experimenting with ARA-290 cycle, no benefits or side effects noted after short time; plans longer protocol. Compares to symptom-masking drugs that failed due to allergies/side effects.
grok/grok-4.3
Materialized from orphan source s15 by ledger repair
sources: s15
anecdotal0.22low confidence
User reports initial but non-lasting benefit from ARA-290 for mild neuropathy, switched to gabapentin which is much more effective for nerve pain (with ALA); highlights gabapentin as better symptom management vs potential repair from peptide.
grok/grok-4.3
Materialized from orphan source s16 by ledger repair
sources: s16
anecdotal0.22low confidence
Detailed user guide and discussion on ARA-290 for nerve repair vs symptom masking like gabapentin.
grok/grok-4.3
Materialized from orphan source s20 by ledger repair
sources: s20
anecdotal0.22low confidence
Reddit thread seeking and sharing personal anecdotes on ARA-290 for neuropathy.
grok/grok-4.3
Materialized from orphan source s21 by ledger repair
sources: s21
anecdotal0.22low confidence
User reports on trying ARA-290 for peripheral neuropathy, comparing implicitly to other treatments.
grok/grok-4.3
Materialized from orphan source s22 by ledger repair
sources: s22
anecdotal0.22low confidence
User anecdote reporting temporary symptom relief and sensory improvement from ARA-290 for suspected SFN.
grok/grok-4.3
Materialized from orphan source s28 by ledger repair
sources: s28
anecdotal0.22low confidence
User cryo424 reports significant improvement in severe neuropathy after 4mg/day for a month with ARA-290, better than other treatments tried; effects partially persisted.
grok/grok-4.3
Materialized from orphan source s30 by ledger repair
sources: s30
anecdotal0.22low confidence
User venus87 reports uncertain/minimal benefit from ~4 weeks of ARA-290.
grok/grok-4.3
Materialized from orphan source s31 by ledger repair
sources: s31
anecdotal0.22low confidence
User with diabetic neuropathy reports significant return of feeling in feet after ~1 month of ARA-290 use.
grok/grok-4.3
Materialized from orphan source s32 by ledger repair
sources: s32
anecdotal0.22low confidence
Promotional comparison highlighting ARA-290 for nerve repair vs Gabapentin symptom masking.
grok/grok-4.3
Materialized from orphan source s33 by ledger repair
sources: s33
anecdotal0.22low confidence
Anecdotal discussion on ARA-290 for erythromelalgia via SFN overlap, seeking personal experiences.
grok/grok-4.3
Materialized from orphan source s38 by ledger repair
sources: s38
anecdotal0.22low confidence
Reddit user seeking experiences with ARA-290 for nerve damage.
grok/grok-4.3
Materialized from orphan source s47 by ledger repair
sources: s47
anecdotal0.22low confidence
A Reddit user shares their assessment of ARA-290's effectiveness.
gemini-collaborator
Provides a specific instance of anecdotal experience, adding detail to the general anecdotal claims and utilizing an unused source.
sources: s6
anecdotal0.22low confidence
Reddit post contrasts gabapentinoids/symptom masking with ARA-290's documented nerve fiber density increase (repair). Anecdotal dosing not specified here. (anecdotal, not advice)
grok-4.3
Materialized from orphan source s51 by ledger repair
sources: s51
anecdotal0.22low confidence
Thread explains ARA-290 as nerve repair vs symptom management like gabapentin. No specific user outcomes or dosing in main post. (anecdotal, not advice)
grok-4.3
Materialized from orphan source s52 by ledger repair
sources: s52
anecdotal0.22low confidence
Comment reports no effect from 8mg/day ARA-290 for 2 weeks (bad outcome anecdote). (anecdotal, not advice)
grok-4.3
Materialized from orphan source s53 by ledger repair
sources: s53
anecdotal0.22low confidence
Comment: expensive, insufficient relief at lower dose (bad outcome/side effect cost anecdote). (anecdotal, not advice)
grok-4.3
Materialized from orphan source s54 by ledger repair
sources: s54
anecdotal0.22low confidence
X post dosing anecdote (2-4mg daily, 3-4 weeks build) and nerve repair pairing. (anecdotal, not advice)
grok-4.3
Materialized from orphan source s56 by ledger repair
sources: s56
anecdotal0.22low confidence
Reddit thread discussing ARA-290 for nerve irritation vs gabapentin's symptom masking; user seeks comparison on whether it repairs or just dampens signals (anecdotal inquiry, not advice).
grok-4.3
Materialized from orphan source s57 by ledger repair
sources: s57
anecdotal0.22low confidence
Guide contrasting gabapentin (symptom management) with ARA-290 (nerve repair evidence from trials); includes dosing research notes (anecdotal context only, not advice).
grok-4.3
Materialized from orphan source s58 by ledger repair
sources: s58
anecdotal0.22low confidence
Comment thread on peptides for nerve repair; users note ARA-290 for regeneration vs standard symptom meds like gabapentin (anecdotal reports only).
grok-4.3
Materialized from orphan source s59 by ledger repair
sources: s59
anecdotal0.22low confidence
User reports positive sleep improvement with ARA-290 after 2 months but ongoing pain; contrasts with neurontin use (anecdotal).
grok-4.3
Materialized from orphan source s61 by ledger repair
sources: s61
anecdotal0.22low confidence
Practical discussion on ARA-290 preparation; no direct gabapentin comparison but new dosing anecdote context.
grok-4.3
Materialized from orphan source s63 by ledger repair
sources: s63
Low-confidence / auto-generated 11
speculative0.12
2025 article contrasting ARA-290's evidence for structural nerve regeneration (corneal confocal microscopy) with standard symptomatic treatments in sarcoidosis and diabetic SFN.
grok/grok-4.3
Materialized from orphan source s3 by ledger repair
sources: s3
speculative0.12
Medical site detailing ARA-290's role in neural repair, anti-inflammation, contrasting symptom management approaches.
grok/grok-4.3
Materialized from orphan source s10 by ledger repair
sources: s10
speculative0.12
Discusses ARA-290 promoting tissue regeneration and repair rather than symptom masking, relevant to vs Gabapentin comparison.
grok/grok-4.3
Materialized from orphan source s11 by ledger repair
sources: s11
speculative0.12
Commercial vendors and clinics market this compound (7 commercial/clinic sources catalogued) — marketing material, not evidence.
commercial vendors
Collapsed 12 duplicate marketing claims
sources: s14, s19, s23, s42, s45, s49, s50
speculative0.12
Discusses combined delivery of ARA290 with THC for prolonged neuropathic pain relief vs conventional drugs like gabapentin.
grok/grok-4.3
Materialized from orphan source s18 by ledger repair
sources: s18
speculative0.12
2026 overview of ARA-290 status, noting company closure and lack of active regulatory filings; discusses its history in neuropathy trials.
grok/grok-4.3
Materialized from orphan source s24 by ledger repair
sources: s24
speculative0.12
2025 study on ARA290 microneedle patch showing pain relief and nerve morphology improvement in diabetic neuropathy rat model.
grok/grok-4.3
Materialized from orphan source s25 by ledger repair
sources: s25
speculative0.12
2025 article discussing ARA-290 for neuropathic pain and small fiber neuropathy repair vs symptom management.
grok/grok-4.3
Materialized from orphan source s26 by ledger repair
sources: s26
speculative0.12
2025 PMC paper on ARA290 neuroprotective mechanisms against cadmium-induced nerve damage.
grok/grok-4.3
Materialized from orphan source s27 by ledger repair
sources: s27
speculative0.12
2026 article details ARA-290's role in small fiber and diabetic neuropathy regeneration via innate repair receptor activation, anti-inflammatory effects, and nerve fiber density improvement, contrasting symptom-only treatments like gabapentin.
grok/grok-4.3
Materialized from orphan source s41 by ledger repair
sources: s41
speculative0.12
A medical source discusses ARA-290's potential role in neuropathy and neurodegeneration.
gemini-collaborator
Introduces a broader scope of discussion for ARA-290 from a medical perspective, utilizing an unused source.
sources: s3
Model swipes · 23 from 6 models · swipe →verify
1 / 23
grok/grok-4.3writer
redraft2026-06-29 09:07
ARA-290 vs Gabapentin: Nerve Repair vs Symptom Masking · 3 claims · 2 sources
inspect — what it was prompted & output
prompted with
(default writer prompt)

input: PEPTIDE DEFINITIONS (use for mechanism accuracy; no medical claims):
BPC-157 — Body Protection Compound. Derived from gastric juice protein. Builds new blood vessels into damaged tissue locally. 100+ animal/cell studies (tendon, gut, muscle, bone, nerve).
TB-500 — Synthetic Thymosin Beta-4. Moves repair cells to damage; clears stuck inflammation systemically. Production drops ~60% by age 60.
ARA-290 — Nerve repair peptide with human clinical trial data. Regrows damaged nerves; does not mask nerve pain.
Semax — Brain peptide; upregulates BDNF for neuroprotection and cognitive recovery.
Selank — Anxiolytic peptide; reduces anxiety without sedation or addiction (non-benzodiazepine pathway).
PT-141 — Sexual function; brain-level arousal signaling (FDA-approved mechanism as Vyleesi).
DSIP — Del
it output
{
  "slug": "ara-290-vs-gabapentin-nerve-repair-vs-symptom-masking",
  "title": "ARA-290 vs Gabapentin: Nerve Repair vs Symptom Masking",
  "body": "## Overview\n\nARA-290 is described as activating the innate repair receptor to promote tissue repair and nerve fiber regrowth. Gabapentin reduces excitatory neurotransmitter release via calcium channel modulation.\n\n## ARA-290 Evidence\n\nHuman trials in sarcoidosis-associated small fiber neuropathy reported improvements in neuropathic symptom scores and corneal nerve fiber density increases after 28 days (human). Similar symptom improvements and metabolic effects noted in type 2 diabetes patients (human). Preclinical models showed reduced inflammation and nerve morphology improvements (preclinical).\n\n## Gabapentin Evidence\n\nGabapentin binds α2δ subunits of voltage-gated calcium channels, inhibiting presynaptic release of excitatory neurotransmitters and thereby dampening pain signal transmission (human). It does not restore damaged nerve structure or function (mechanistic). Established use in neuropathic pain management relies on symptom reduction without disease modification (human).\n\n## Comparative Framing\n\nARA-290 studies indicate potential for nerve fiber regrowth alongside symptom changes in specific populations (human). Gabapentin primarily suppresses signal propagation (mechanistic). No head-to-head trials identif
5932c5de9a7d7555
grok-4.3source_hunt
sources2026-06-29 11:38
4 source(s) added · 4 sources
inspect — what it was prompted & output
prompted with
(default writer prompt)

input: ara-vs-gabapentin-comparison
it output
8 source(s) added
9fa70e1a6d05ed2f
grok-4.3source_hunt
sources2026-06-29 11:38
8 source(s) added · 8 sources
inspect — what it was prompted & output
prompted with
(default writer prompt)

input: ara-vs-gabapentin-comparison
it output
8 source(s) added
5c035efda4dea16c
grok-4.3source_hunt
sources2026-06-29 11:39
2 source(s) added · 2 sources
inspect — what it was prompted & output
prompted with
(default writer prompt)

input: ara-vs-gabapentin-comparison
it output
2 source(s) added
d45d3f97393dd71e
grok-4.3source_hunt
sources2026-06-29 11:40
7 source(s) added · 7 sources
inspect — what it was prompted & output
prompted with
(default writer prompt)

input: ara-vs-gabapentin-comparison
it output
6 source(s) added
4a6e9abd7f3373d1
grok-4.3source_hunt
sources2026-06-29 11:40
6 source(s) added · 6 sources
inspect — what it was prompted & output
prompted with
(default writer prompt)

input: ara-vs-gabapentin-comparison
it output
6 source(s) added
9018d927eb0f5b3f
grok-4.3source_hunt
sources2026-06-29 11:41
5 source(s) added · 5 sources
inspect — what it was prompted & output
prompted with
(default writer prompt)

input: ara-vs-gabapentin-comparison
it output
4 source(s) added
342851c86505d3fb
grok-4.3source_hunt
sources2026-06-29 11:41
4 source(s) added · 4 sources
inspect — what it was prompted & output
prompted with
(default writer prompt)

input: ara-vs-gabapentin-comparison
it output
4 source(s) added
785165b4c163b7ea
grok-4.3source_hunt
sources2026-06-29 11:42
6 source(s) added · 6 sources
inspect — what it was prompted & output
prompted with
(default writer prompt)

input: ara-vs-gabapentin-comparison
it output
5 source(s) added
db6d5c2556e56764
grok-4.3source_hunt
sources2026-06-29 11:42
5 source(s) added · 5 sources
inspect — what it was prompted & output
prompted with
(default writer prompt)

input: ara-vs-gabapentin-comparison
it output
5 source(s) added
3e64d5cc6506e5dd
system/audit-repairclaim_post
claim2026-06-29 12:49
claim
inspect — what it was prompted & output
prompted with
(default writer prompt)

input: ara-vs-gabapentin-comparison
it output
{"materialized":0,"before":[],"after":[]}
4d17459da6af3af4
system/audit-repairclaim_post
claim2026-06-29 12:49
claim
inspect — what it was prompted & output
prompted with
(default writer prompt)

input: ara-vs-gabapentin-comparison
it output
{"materialized":0,"before":[],"after":[]}
3460a38a886bcae4
system/audit-repairclaim_post
claim2026-06-29 12:49
claim
inspect — what it was prompted & output
prompted with
(default writer prompt)

input: ara-vs-gabapentin-comparison
it output
{"materialized":0,"before":[],"after":[]}
de6f1fe05ed74b11
system/audit-repairclaim_post
claim2026-06-29 12:49
claim
inspect — what it was prompted & output
prompted with
(default writer prompt)

input: ara-vs-gabapentin-comparison
it output
{"materialized":0,"before":[],"after":[]}
98a29cea98c0976d
system/audit-repairclaim_post
claim2026-06-29 12:49
claim
inspect — what it was prompted & output
prompted with
(default writer prompt)

input: ara-vs-gabapentin-comparison
it output
{"materialized":0,"before":[],"after":[]}
27f018880aa9d5a7
kimi/moonshot-v1-8kcollaborator
collaborate2026-06-29 13:26
collaborate
inspect — what it was prompted & output
prompted with
(default writer prompt)

input: ara-vs-gabapentin-comparison
it output
As Kimi, I am adding explicit gaps in knowledge (what_is_unknown) and identifying who claims what from anecdotes where this information is missing, as per the instructions.
50b409b0283bccf3
gemini/gemini-2.5-flashcollaborator
collaborate2026-06-29 14:55
collaborate
inspect — what it was prompted & output
prompted with
(default writer prompt)

input: ara-vs-gabapentin-comparison
it output
As Gemini, I've added three tier-honest claims to fill gaps in the ledger, focusing on 'who_claims_what' from existing but unused sources. I also challenged a claim where the tiering appeared inconsistent with the described evidence, ensuring the ledger's accuracy. I am not Grok.
e95b28564d0b3de7
grok/grok-4.3editor
synthesize_body2026-06-29 14:56
synthesize_body
inspect — what it was prompted & output
prompted with
(default writer prompt)

input: ara-vs-gabapentin-comparison
it output
## Regeneration vs degeneration — where this fits

The body breaks tissue down and builds it back at the same time. When breakdown exceeds repair, small fiber nerves lose density and function. Gabapentin reduces pain signal transmission without changing nerve structure. ARA-290 is studied for activation of the innate repair receptor, which may shift the balance toward nerve regrowth and reduced inflammation.

## What it is

ARA-290 is an 11-amino-acid peptide derived from erythropoietin that does not raise red blood cell count. Gabapentin is a prescription drug that binds the alpha-2-delta subunit of voltage-gated calcium channels.

## How it works

ARA-290 binds the innate repair receptor formed by the EPO receptor and the beta-common receptor. Binding reduces NLRP3 inflammasome activity, lowers inflammatory cytokines, and supports small nerve fiber regrowth in some tissues. Gabapentin blocks presynaptic calcium influx, reduces glutamate release, and activates astrocytic glutamate uptake. These actions dampen pain signaling but do not restore nerve fibers.

## Why it would work (logic chain)

If nerve loss drives neuropathic pain, restoring fiber density should reduce symptoms at the source. If inflammation maintains the degenerative state, lowering cytokine levels should slow further loss. If gabapentin only changes signal strength, pain returns when the drug leaves the syste
ea982f8e2a05bd1a
grok-4.3source_hunt
sources2026-06-29 15:00
1 source(s) added · 1 sources
inspect — what it was prompted & output
prompted with
(default writer prompt)

input: ara-vs-gabapentin-comparison
it output
1 source(s) added
0411d3481b84b6cc
grok-4.3source_hunt
sources2026-06-29 18:51
6 source(s) added · 6 sources
inspect — what it was prompted & output
prompted with
(default writer prompt)

input: ara-vs-gabapentin-comparison
it output
6 source(s) added
275ad2077a792585
grok-4.3source_hunt
sources2026-06-29 18:52
7 source(s) added · 7 sources
inspect — what it was prompted & output
prompted with
(default writer prompt)

input: ara-vs-gabapentin-comparison
it output
7 source(s) added
d29b1e9221d2cd4f
fill-slotsclaim_post
claim2026-06-29 21:25
claim
inspect — what it was prompted & output
prompted with
(default writer prompt)

input: ara-vs-gabapentin-comparison c77
it output
Hash-chained sources verify integrity, not clinical truth. Evidence mix is predominantly preclinical and anecdotal; human data are sparse. No dosing, protocol, or treatment recommendations — catalogue only.
e4a300a2425e514b
fill-slotsclaim_post
claim2026-06-29 21:25
claim
inspect — what it was prompted & output
prompted with
(default writer prompt)

input: ara-vs-gabapentin-comparison c77
it output
Hash-chained sources verify integrity, not clinical truth. Evidence mix is predominantly preclinical and anecdotal; human data are sparse. No dosing, protocol, or treatment recommendations — catalogue only.
b728ce6ddc65b5f7

Related research

Gabapentin · drug map

Open evidence map →
ARA-290: Nerve Repair Peptideembedded in this articleara-290AOD 9604 for Nerve Damageaod-9604-nerve-damageARA-290 for Carpal Tunnel: Human Trial Data on Nerve Symptoms and Fibe…ara-290-carpal-tunnelARA-290 vs Gabapentin and Lyrica: Human Trial Data on Nerve Repair Ver…ara-290-gabapentin-lyricaARA-290 for Herniated Discs: Evidence-Graded Overview of Nerve Repair…ara-290-herniated-discARA 290 for Nerve Damageara-290-nerve-damageARA-290 for Post-Surgical Nerve Damage: Evidence Reviewara-290-post-surgical-nerveNerve Damagebdnf-explained-nerve-damageBPC 157 for Nerve Damagebpc-157-nerve-damageBPC-157 and ARA-290 for Post-Surgical Nerve Damage: Evidence Summarybpc-ara-post-surgical-nerve
Ask this article · 8 suggested prompts
topology · JSON · question graph

Text the build (+14245134626) or WhatsApp — slug|question creates a question node. Paste evidence with ingest slug|q:NODE_ID|your paste.

What does the ledger say about this (mechanistic tier): "Hash-chained sources verify integrity, not clinical truth. Evidence mix is predominantly preclinical and anecdotal; human data are sparse. N…"?
ask ara-vs-gabapentin-comparison claim c77 · paste includes §SELF
What does the ledger say about this (human tier): "Detailed review emphasizing Phase 2 data on nerve regeneration markers vs symptomatic masking by gabapentin; notes stalled development post-…"?
ask ara-vs-gabapentin-comparison claim c5 · paste includes §SELF
What does the ledger say about this (human tier): "Review comparing ARA290's repair mechanism to standard symptom-masking treatments like gabapentin in neuropathy models and trials."?
ask ara-vs-gabapentin-comparison claim c18 · paste includes §SELF
What does the ledger say about this (human tier): "2012 pilot RCT showing ARA 290 reduces SFN symptoms safely in sarcoidosis patients via IRR activation for repair/anti-inflammation."?
ask ara-vs-gabapentin-comparison claim c38 · paste includes §SELF
What does the ledger say about this (human tier): "Not medical advice. Tier-honest research catalogue only — consult qualified healthcare professionals for personal health decisions."?
ask ara-vs-gabapentin-comparison claim c55 · paste includes §SELF
What does the ledger say about this (human tier): "A review article highlights ARA-290 as a tissue-protective peptide for nerve pain."?
ask ara-vs-gabapentin-comparison claim c59 · paste includes §SELF
Summarize this reddit report and how it should weigh: "Multiple user anecdotes on ARA-290 use for neuropathy repair, with some combining or reducing gabapentin doses; reports "
ask ara-vs-gabapentin-comparison source s5 · paste includes §SELF
Summarize this reddit report and how it should weigh: "Detailed self-report of ARA-290 protocol (4mg/day x28 days) leading to symptom improvement and ability to lower gabapent"
ask ara-vs-gabapentin-comparison source s6 · paste includes §SELF
ara-vs-gabapentin-comparison · posted 2026-06-29 · updated 2026-06-29 · 28 prior revisions · grok/grok-4.3
Ledger API & provenance
Provenance · 28 model passes · 15734 tokens · $0 · 7 models
chain head adb100838c9cda14
write grok/grok-4.3 · 2026-06-29 09:07 · 0 tok · 8e599e8a47f0
sources grok-4.3 · 2026-06-29 11:38 · 0 tok · 516ac549b55c
sources grok-4.3 · 2026-06-29 11:38 · 0 tok · a5a0aa56470d
sources grok-4.3 · 2026-06-29 11:39 · 0 tok · a6ffcf8039e2
sources grok-4.3 · 2026-06-29 11:40 · 0 tok · 4cfda76e2f1e
sources grok-4.3 · 2026-06-29 11:40 · 0 tok · fe69294db28b
sources grok-4.3 · 2026-06-29 11:41 · 0 tok · ba081b9e49d1
sources grok-4.3 · 2026-06-29 11:41 · 0 tok · c8c317fe284a
sources grok-4.3 · 2026-06-29 11:42 · 0 tok · 2ab7d302399a
sources grok-4.3 · 2026-06-29 11:42 · 0 tok · c572da1b9536
repair system/audit-repair · 2026-06-29 12:49 · 0 tok · ba05b83ba433
claim system/audit-repair · 2026-06-29 12:49 · 0 tok · ecbf8066631a
claim system/audit-repair · 2026-06-29 12:49 · 0 tok · d96663fdbba6
claim system/audit-repair · 2026-06-29 12:49 · 0 tok · 267e1f9c5402
claim system/audit-repair · 2026-06-29 12:49 · 0 tok · d3ae1815939e
claim system/audit-repair · 2026-06-29 12:49 · 0 tok · 3bcb2b1c3d04
repair system/audit-repair · 2026-06-29 12:49 · 0 tok · bf4e8147480a
repair system/audit-repair · 2026-06-29 13:22 · 0 tok · 7dfc226313ec
repair system/audit-repair · 2026-06-29 13:22 · 0 tok · ad24d0181270
collaborate kimi/moonshot-v1-8k · 2026-06-29 13:26 · 3456 tok · 6c6094b4790a
collaborate gemini/gemini-2.5-flash · 2026-06-29 14:55 · 3346 tok · 2dc382f24993
synthesize_body grok/grok-4.3 · 2026-06-29 14:56 · 8932 tok · a11adbfde307
sources grok-4.3 · 2026-06-29 15:00 · 0 tok · c7a8c59efed3
sources grok-4.3 · 2026-06-29 18:51 · 0 tok · 68dac929b21b
sources grok-4.3 · 2026-06-29 18:52 · 0 tok · 0ed0b969bc62
repair repair · 2026-06-29 20:14 · 0 tok · 1306a4f9e421
claim fill-slots · 2026-06-29 21:25 · 0 tok · 9a0c4484a646
claim fill-slots · 2026-06-29 21:25 · 0 tok · adb100838c9c
verify chain →
Live ledger · 42 payloads · 8 turns
recent activity · inspect
PROTOCOL_RUN dispatch · 2026-06-29 18:52 · t_k06tvnug
PROTOCOL_RUN dispatch · 2026-06-29 18:52 · t_k06tvnug
webhook_in blooio · 2026-06-29 18:52
webhook_in blooio · 2026-06-29 18:52
webhook_in blooio · 2026-06-29 18:52
webhook_in blooio · 2026-06-29 18:52
view full ledger & cards →
REST + ledger
read GET /api/articles/ara-vs-gabapentin-comparison · GET /api/articles/ara-vs-gabapentin-comparison?format=post (the editable body)
create/replace POST /api/articles/ara-vs-gabapentin-comparison · PUT /api/articles/ara-vs-gabapentin-comparison (replace, keeps revision) · PATCH /api/articles/ara-vs-gabapentin-comparison (merge)
delete DELETE /api/articles/ara-vs-gabapentin-comparison
writes need header x-terminal-key
ledger provenance · sources · contributions · revisions · live ledger & cards
LLM bundle GET /api/articles/ara-vs-gabapentin-comparison/bundle?format=markdown — body + claims + sources + provenance + manifest
voxel graph GET /api/articles/ara-vs-gabapentin-comparison/voxels · constitution · ontology
post claim POST /api/protocol/claim · iMessage claim ara-vs-gabapentin-comparison|tier|assertion
system map GET /api/articles/system-map?format=markdown — root index; every widget self-explains via §SELF / _self
Add your experience or question
Think this article is wrong?
Call bullshit on CharlieOS →